Abstract: ObjectiveTo explore the clinical curative effect on nonsmall cell lung cancer (NSCLC) patients by cinobufacini injection combined with firstline chemotherapy. MethodsEighty patients with NSCLC from January 2013 to January 2015 in our hospital were selected as the research objects. Then they were divided into the observation group (n=40) and the control group (n=40) by random number tables. The patients in control group accepted docetaxel and cisplatin combination chemotherapy regimens (TP). While the observation group accepted cinobufacini injection on the basis of the control group. Then the local control, adverse reactions and prognosis of the two groups were compared. ResultsThe local control of observation group was 77.5%, while the control group was 62.5%, the local control of observation group was obviously higher than that of the control group (χ2=5.36, P=0.03). Leucopenia incidence of the observation group was 27.5%, the control group was 50.0%, and the incidence of the observation group was obviously lower than that of the control group (χ2=4.27, P=0.04). There was no statistically significant difference between the two groups in diarrhea, stomachache, vomiting, tinnitus (17.5% vs. 27.5%, χ2=1.15， P=0.28； 25.0% vs. 45.0%, χ2=3.52， P=0.06;  5.0% vs. 7.5%, χ2=0.34， P=0.56； 7.5% vs. 10.0%, χ2=0.16， P=0.69). There was statistically significant difference between the two groups in median survival time (97 d vs. 45 d, HR=8.934, χ2=9.928, P＜0.05). ConclusionThe cinobufacini injection combined with docetaxel can effectively reduce the incidence of myelosuppression, and improve survival and local control with high safety, and the clinical effect is remarkable and can improve the prognosis of patients.

Key words: Carcinoma, nonsmall cell lung, Taxoids, Cinobufacini injection